Pharmacokinetic interaction between fluoxetine and omeprazole in healthy male volunteers: a prospective pilot study.

Simultaneous administration of fluoxetine and simvastatin ameliorates lipid profile, improves brain level of neurotransmitters, and increases bioavailability of simvastatin. J Exp Pharmacol (2017) 0.75

A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm (1987) 8.01

Clinical pharmacokinetics of fluoxetine. Clin Pharmacokinet (1994) 1.45

Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism. Br J Clin Pharmacol (1994) 1.28

Oxidative metabolism of omeprazole in human liver microsomes: cosegregation with S-mephenytoin 4'-hydroxylation. J Pharmacol Exp Ther (1993) 1.16

Omeprazole drug interaction studies. Clin Pharmacokinet (1991) 1.09

Omeprazole. An updated review of its pharmacology and therapeutic use in acid-related disorders. Drugs (1991) 1.09

Clinically significant drug interactions with antidepressants in the elderly. Drugs Aging (2002) 1.04

Different inhibitory effect of fluvoxamine on omeprazole metabolism between CYP2C19 genotypes. Br J Clin Pharmacol (2004) 1.01

Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors? Eur J Clin Pharmacol (2006) 0.98

Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror. Int Clin Psychopharmacol (1995) 0.95

CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori. Clin Pharmacol Ther (1999) 0.93

Omeprazole: pharmacokinetics and metabolism in man. Scand J Gastroenterol Suppl (1989) 0.92

CYP2C19 genotype related effect of omeprazole on intragastric pH and antimicrobial stability. Pharm Res (2001) 0.89

Pharmacokinetic interactions between omeprazole/pantoprazole and clarithromycin in health volunteers. Pharmacol Res (2004) 0.88

Assessment of the potential for a pharmacokinetic interaction between fluoxetine and terfenadine. Clin Pharmacol Ther (1997) 0.86

Relative efficacies of gastric proton pump inhibitors: their clinical and pharmacological basis. Pharmacology (1999) 0.84

Effect of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapine. J Clin Psychopharmacol (2002) 0.80

Pharmacokinetic profile of talipexole in healthy volunteers is not altered when it is co-administered with Madopar (co-beneldopa). J Clin Pharm Ther (2009) 0.79